Cipla informs about updates

25 Jun 2024 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to intimation dated 4th April 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at Patalganga manufacturing facility, Cipla has informed that the United States Food and Drug Administration (USFDA) vide communication dated Tuesday, 25th June 2024 (12:37 AM IST) has classified the above referred inspection as Voluntary Action Indicated (VAI).

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1515.45 18.95 (1.27%)
17-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1751.05
Dr. Reddys Lab 1163.70
Cipla 1515.45
Lupin 1936.75
Zydus Lifesciences 831.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...